argenx SE American Depositary Shares - ARGX STOCK NEWS

argenx (Euronext & Nasdaq: ARGX) will host a virtual R&D Day on July 20, 2021, at 3:00 p.m. CET (9:00 a.m. ET) to unveil its 'argenx 2025 vision' and update its immunology pipeline. Key announcements include the introduction of new indications for the FcRn antagonist, efgartigimod, alongside Phase 1 data for ARGX-117. The event features expert discussions, including Dr. Rohit Aggarwal and Dr. Russell P. Hall III. A dedicated microsite will host a live webcast and further resources. Access it through the argenx investors' page.

Argentx announced positive results from the Phase 3 ADAPT trial of efgartigimod, a treatment for generalized myasthenia gravis (gMG). The trial showed that 67.7% of patients treated with efgartigimod experienced significant improvement on the Myasthenia Gravis Activities of Daily Living (MG-ADL) score compared to 29.7% in the placebo group (p<0.0001). Efgartigimod is under FDA review with a PDUFA target action date of December 17, 2021. If approved, it would be the first FcRn antagonist for gMG, aiming to improve the quality of life for patients suffering from this debilitating disease.

On June 7, 2021, argenx SE (ARGX) announced it regained worldwide rights to the anti-CD70 antibody cusatuzumab from Cilag GmbH International. Interim data from the Phase 1b ELEVATE trial shows promising results for cusatuzumab in treating acute myeloid leukemia (AML), with a 48% complete remission rate and an overall response rate of 93%. The trial involves 44 patients, indicating cusatuzumab's potential benefits while being well-tolerated. The collaboration with Janssen was initiated in 2018, bringing in $525 million in payments and investments, but was recently discontinued.

On June 1, 2021, argenx announced the appointment of Mr. Karl Gubitz as Chief Financial Officer, succeeding Eric Castaldi, who will remain until June 30, 2021. Gubitz, with nearly 20 years of experience in global pharmaceutical finance, previously held a Vice President role at Pfizer. His expertise is expected to strengthen argenx's strategic financial direction as the company approaches the anticipated commercial launch of its lead product, efgartigimod. Gubitz's appointment comes during a pivotal time for the company, enhancing its position in the immunology sector.

argenx (Euronext & Nasdaq: ARGX) announced management's participation in several upcoming investor conferences. Key events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, JMP Securities Life Sciences Conference on June 16, J.P. Morgan European Healthcare Conference on June 17, and Raymond James Human Health Innovation Conference on June 22, 2021. The company focuses on developing treatments for severe autoimmune diseases and cancer, including efgartigimod and cusatuzumab.

argenx reported strong first-quarter 2021 results with revenue soaring to $158 million, a significant increase from $21 million in Q1 2020. The company announced that the Japanese Marketing Authorization Application for efgartigimod was accepted for review, following similar FDA acceptance in the U.S. with a target decision date of December 17, 2021. The firm is advancing registrational trials across multiple indications and plans to initiate two additional indications this year. Cash and equivalents reached $2.9 billion, bolstered by a public offering that raised $1.15 billion.

On May 11, 2021, argenx SE held its Annual General Meeting of Shareholders where all proposed resolutions were passed. Key decisions included the appointment of Yvonne Greenstreet and re-appointment of Anthony Rosenberg as non-executive directors for four-year terms. The Board was authorized to issue additional shares up to 10% of share capital for 18 months. The 2020 remuneration report and new remuneration policy were approved, and Deloitte Accountants B.V. was appointed as the auditor for 2021. Dr. David Lacey resigned from the Board but will serve in an advisory role.

argenx (Euronext & Nasdaq: ARGX) will host a conference call and audio webcast on May 14, 2021, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its Q1 2021 financial results and present a business update.

Investors can access the call via the Investors section of the argenx website. The company is focused on advancing innovative antibody therapies for severe autoimmune diseases and cancer.

argenx (Euronext & Nasdaq: ARGX), a global immunology company, announced management participation in two upcoming conferences. The Kempen Life Sciences Conference will include investor meetings on May 5, 2021, while a BofA Securities Virtual Healthcare Conference will feature a fireside chat on May 13, 2021, at 8:00 a.m. ET. The company focuses on developing treatments for severe autoimmune diseases and cancer, working with leading researchers through its Immunology Innovation Program.